Navigation Links
Indevus Announces Allergan as New Partner for SANCTURA Brand
Date:9/19/2007

achieving new levels of success in our co-promotion of SANCTURA XR."

On August 6, 2007, Indevus announced that SANCTURA XR (trospium chloride extended release capsules) was approved by the U.S. Food and Drug Administration (FDA). SANCTURA XR is indicated for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Following the approval, the Company received a $49.9 million milestone payment from Esprit Pharma, the Company's partner in the U.S. for SANCTURA and SANCTURA XR. The milestone payment was based on the total costs to develop SANCTURA XR, including clinical development, as well as manufacturing development costs.

Under the terms of the amended and restated license, commercialization and supply agreement, Allergan will be responsible for all marketing and sales activities. Indevus will be responsible for supply of SANCTURA XR through June 30, 2008. Beginning in July 2008, Allergan will assume manufacturing responsibilities for SANCTURA XR. Upon closing of this agreement, Allergan will pay Indevus an upfront license fee of $25 million, a portion of which will begin to be creditable by Allergan in 2010, against certain future payments owed to Indevus. Allergan will also pay Indevus royalties on net sales of SANCTURA and SANCTURA XR of 12.5% and will reimburse Indevus for required royalty payments to Indevus' licensors. For a period of seven years, the royalties payable to Indevus will be subject to a guaranteed minimum level, except under specified conditions. The guaranteed minimum royalties will be as follows: 2008 - $8.1 million, 2009 - $10.6 million, 2010 - $15.6 million, 2011 - $18.1 million, 2012 - $20.6 million, 2013 - $23.5 million, 2014 - $26.3 million. Indevus will also receive a milestone payment of $20 million in December 2013 based on certain market exclusivity conditions.

Additionally, Indevus will continue to co-promote SANCTURA XR through September 2008 an
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... COTTAGE, N.Y., Jan. 28 XTL Biopharmaceuticals Ltd. (Nasdaq: ... its December 8, 2008 press release regarding the Company,s activities ... company to merge into or with XTL. The Company is ... it by both US and foreign-based companies who operate in ...
... as VP of Business Development , ... Olyphant, PA (PRWEB) January 28, ... company, announced today the hiring of Mr. Terry Ladd as Vice President ... 1994-2003 as Executive Director, Business Development and Marketing., , , , ,Mr. ...
... PALO ALTO, Calif., Jan. 28 In light of an ... (Nasdaq: CVTX ) confirmed that it had received ... an unsolicited proposal by Astellas to acquire CV Therapeutics at ... Astellas board approval and other conditions. After careful deliberation, ...
Cached Biology Technology:XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives 2Calvert Labs Announces the Hiring of Terry Ladd 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: reusable ...
... LS Low Speed Shaker ,Product ... speed shaker is a high quality, general purpose ... ,Styled after the other models in the line, ... with easy-access control panel. Electronic controls are utilized ...
... CromoCenSC is a chromogenic medium for ... of Salmonella (except S. thyphi) and ... ,The detection takes a maximum of ... tests, no sterilization during preparation and ...
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
Biology Products: